Skip to main content

Table 3 Work productivity and activity impairment questionnaire

From: Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Instrument Subscale/

ETN + MTX

DMARD + MTX

P value*

 Time on Therapy

Mean Score (% Improvement from Baseline) (N)

 

Percent activity impairment due to health

   

 Baseline

58.6 (0%) (N = 197)

58.6 (0%) (N = 103)

 

 Week 16

30.0 (48.7%) (N = 186)

41.0 (29.3%) (N = 83)

< 0.001

Percent impairment while working due to health problem

   

 Baseline

48.9 (0%) (N = 62)

51.4 (0%) (N = 37)

 

 Week 16

24.1 (49.6%) (N = 54)

37.3 (23.6%) (N = 26)

0.012

Percent overall work impairment due to health problem

   

 Baseline

52.3 (0%) (N = 61)

56.3 (0%) (N = 37)

 

 Week 16

25.1 (51.0%) (N = 53)

41.6 (22.0%) (N = 26)

0.004

Percent work time missed due to health

   

 Baseline

10.6 (0%) (N = 63)

14.9 (0%) (N = 37)

 

 Week 16

2.04 (80.7%) (N = 55)

10.7 (21.7%) (N = 26)

0.002

  1. General Health at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN + MTX versus DMARD + MTX (Observed Case Analysis).
  2. DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; MTX: methotrexate.
  3. *ANCOVA, considering the factors ‘baseline score + therapy + country’.